Asset Details
Do you wish to reserve the book?
Cell and animal models of SARS-CoV-2 pathogenesis and immunity
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cell and animal models of SARS-CoV-2 pathogenesis and immunity
Do you wish to request the book?
Cell and animal models of SARS-CoV-2 pathogenesis and immunity
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cell and animal models of SARS-CoV-2 pathogenesis and immunity
2020
Overview
The spread of the novel virus SARS coronavirus 2 (SARS-CoV-2) was explosive, with cases first identified in December 2019, and >22 million people infected and >775,000 deaths as of August 2020. SARS-CoV-2 can cause severe respiratory disease in humans leading to coronavirus disease 2019 (COVID-19). The development of effective clinical interventions, such as antivirals and vaccines that can limit or even prevent the burden and spread of SARS-CoV-2, is a global health priority. Testing of leading antivirals, monoclonal antibody therapies and vaccines against SARS-CoV-2 will require robust animal and cell models of viral pathogenesis. In this Special Article, we discuss the cell-based and animal models of SARS-CoV-2 infection and pathogenesis that have been described as of August 2020. We also outline the outstanding questions for which researchers can leverage animal and cell-based models to improve our understanding of SARS-CoV-2 pathogenesis and protective immunity. Taken together, the refinement of models of SARS-CoV-2 infection will be critical to guide the development of therapeutics and vaccines against SARS-CoV-2 to end the COVID-19 pandemic.
Publisher
The Company of Biologists Ltd,The Company of Biologists
Subject
/ Animals
/ Antiviral Agents - therapeutic use
/ Betacoronavirus - drug effects
/ Betacoronavirus - immunology
/ Betacoronavirus - pathogenicity
/ Coronavirus Infections - drug therapy
/ Coronavirus Infections - immunology
/ Coronavirus Infections - prevention & control
/ Coronavirus Infections - virology
/ COVID-19
/ Humans
/ mers-cov
/ Middle East respiratory syndrome
/ Pneumonia, Viral - drug therapy
/ Pneumonia, Viral - immunology
/ sars-cov
/ Severe acute respiratory syndrome coronavirus 2
/ Special
